Risdiplam is the only approved small molecule mRNA splice modifier to date. Over more than five years since its first approval, thousands of patients with spinal muscular atrophy have benefited from risdiplam therapy. Yet, the nonclinical development of risdiplam was marked by toxicological challenges requiring new strategies and approaches, which ultimately translated into clinical success. This minireview covers key aspects of the nonclinical development of risdiplam, particularly focusing on its toxicological characterization and histopathological features in animal studies.
FinkelRSHughesSHParkerJ, et al. Risdiplam for prenatal therapy of spinal muscular atrophy. N Engl J Med. 2025;392(11):1138-1140. doi:10.1056/NEJMc2300802.
2.
FowlerSBrinkAClearyY, et al. Addressing today’s absorption, distribution, metabolism, and excretion (ADME) challenges in the translation of in vitro ADME characteristics to humans: a case study of the SMN2 mRNA splicing modifier risdiplam. Drug Metab Dispos. 2022;50(1):65-75. doi:10.1124/dmd.121.000563.
3.
HamiltonGGillingwaterTH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013;19(1):40-50. doi:10.1016/j.molmed.2012.11.002.
4.
HeinigKDzygielPFerrariL. Overcoming bioanalytical challenges during the development of risdiplam for the treatment of spinal muscular atrophy. Bioanalysis. 2025;17:1083-1095. doi:10.1080/17576180.2025.2554563.
5.
LeTTPhamLTButchbachME, et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet. 2005;14(6):845-857. doi:10.1093/hmg/ddi078.
6.
MuellerLBarrowPJacobsenBEbelingMWeinbauerG. Reproductive findings in male animals exposed to selective survival of motor neuron 2 (SMN2) gene splicing-modifying agents. Reprod Toxicol. 2023;118:108360. doi:10.1016/j.reprotox.2023.108360.
7.
MüllerLJacobsenBDenkNKustermannSPoirierA. Partial reversal of retinal effects in the recovery phase of a chronic monkey study. Toxicol Sci. 2017;156(1):181.
8.
MüllerLJacobsenBHerrmannAAltmannB. Optical coherence tomography (OCT) correlating with histopathology for peripheral retina degeneration in a chronic monkey toxicity study. Toxicol Sci. 2016;150(1):142.
9.
NaryshkinNAWeetallMDakkaA, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345(6197):688-693. doi:10.1126/science.1250127.
10.
NashLABurnsJKChardonJWKotharyRParksRJ. Spinal muscular atrophy: more than a disease of motor neurons?Curr Mol Med. 2016;16(9):779-792. doi:10.2174/1566524016666161128113338.
11.
OsborneMGomezDFengZ, et al. Characterization of behavioral and neuromuscular junction phenotypes in a novel allelic series of SMA mouse models. Hum Mol Genet. 2012;21(20):4431-4447. doi:10.1093/hmg/dds285.
12.
OttesenEWHowellMDSinghNNSeoJWhitleyEMSinghRN. Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy. Sci Rep. 2016;6:20193. doi:10.1038/srep20193.
13.
PalacinoJSwalleySESongC, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. 2015;11(7):511-517. doi:10.1038/nchembio.1837.
14.
PoirierAWeetallMHeinigK, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018;6(6):e00447. doi:10.1002/prp2.447.
15.
RatniHEbelingMBairdJ, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501-6517. doi:10.1021/acs.jmedchem.8b00741.
16.
RatniHEbelingMScalcoRMuellerLStephanA. SMN2 splicing modification by small molecules—a blueprint to tackle the underlying genetic cause of many underserved diseases. In: WardSDavisA, eds. The Handbook of Medicinal Chemistry: Principles and Practice. 2nd ed. London, UK: The Royal Society of Chemistry; 2023:830-846.
17.
RatniHMuellerLEbelingM. Rewriting the (tran)script: application to spinal muscular atrophy. Prog Med Chem. 2019;58:119-156. doi:10.1016/bs.pmch.2018.12.003.
18.
SergottRCAmorelliGMBaranelloG, et al. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8(1):54-65. doi:10.1002/acn3.51239.
